For those thinking this is sell off is all to do with RAC,...

For those thinking this is sell off is all to do with RAC, here's a comparison chart of RAC and IMU over the last 3 months. I don't really follow or keep up with what's happening with IMU, but they're a different company, with different management and employees, have different products, with different treatment methods and MOA, in different stages of development, with different preclinical and clinical data, a different market cap, a different share price, different cash backing, have different trials running, different relationships with pharma, universities and hospitals, different news flow, and (I assume) have a largely different shareholder base... in fact, what do they have in common other than being a biotech listed on the ASX developing cancer treatments? Yet their price action is almost perfectly in sync.